$26.770
+0.099 (+0.37%)Zum Schluss
AORT-News
AORT-Events
Sees 2026 Adjusted EBITDA of $92M-$99M
Sees 2026 adjusted EBITDA $92M-$99M.
Company Reports Q2 Revenue of $125.8M, Beating Expectations
Reports Q2 revenue $125.8M, consensus $120.01M. "In Q2, we delivered 9% constant currency revenue growth and 7% adjusted EBITDA growth, reflecting continued execution of our strategy to drive long-term, profitable growth through an expanding and clinically differentiated product portfolio," said CEO Pat Mackin. "...Overall, we are pleased with our Q2 performance, which included an acceleration in stent graft revenue and a return to growth across all international geographies. Combined with the AMDS PMA approval, we have even greater confidence in our ability to deliver our full year guidance. We continue to build our broader market expansion pipeline, with ARTIZEN enrolling as expected, and remain confident in our longer-term growth outlook."
Artivion AMDS Hybrid Prosthesis Approved by FDA
Artivion announced that the U.S. FDA has approved the premarket approval application for the AMDS Hybrid Prosthesis. The approval covers acute Debakey Type I aortic dissections with either clinical or radiographic malperfusion, which the company estimates to be approximately 60% of all Debakey Type I aortic dissections. Given this approval, hospitals will no longer be required to obtain institutional review board approval in order to implant AMDS in their institutions, a requirement associated with the Humanitarian Device Exemption. This will reduce administrative burden on hospitals and enabling physicians to treat eligible patients more immediately and broadly across U.S. institutions.
Artivion Completes Acquisition of Endospan for $175M
Endospan announced that Artivion has closed the transaction to acquire the company. This strategic milestone follows the April 2026 U.S. Food and Drug Administration PMA approval of the NEXUS Aortic Arch System. The purchase price for the acquisition is $175M less offsets for previously provided loans, plus a potential for up to $200M in additional consideration contingent upon U.S. NEXUS commercial performance over the next two years. "The FDA approval of the NEXUS system was a pivotal moment for aortic surgeons seeking a technology specifically designed to treat the ascending and aortic arch," said Kevin Mayberry, Chief Executive Officer at Endospan. "With Artivion's acquisition of Endospan, this differentiated technology is being positioned within a company that understands the aortic space through a differentiated portfolio serving the multidisciplinary approach of open, endo and hybrid solutions."
Company Reports Q1 Revenue of $116.3M, Exceeding Expectations
Reports Q1 revenue $116.3M, consensus $115.74M. "In Q1 2026, we achieved 12% constant currency revenue growth and 26% adjusted EBITDA growth, reflecting continued execution of our strategy to deliver long-term, profitable performance with an expanding and clinically differentiated product portfolio. On a constant currency basis, Q1 year-over-year stent grafts, On-X, and preservation services grew 10%, 17%, and 23%, respectively," said CEO Pat Mackin. "We have since exercised our option to acquire Endospan and expect the acquisition to close in the Q2, subject to customary closing conditions...While our first quarter performance fell short of our constant currency expectations due to some transient factors, we are confident that the fundamentals underpinning our strategy remain intact. We are seeing strong reordering behavior within AMDS accounts, which exceeded our expectations and reinforces our conviction in long-term adoption. Meanwhile, On-X continues to take share from both mechanical and bioprosthetic valves as the leading aortic valve on the market for patients under the age of 65."
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.